Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

American Journal of Psychiatry

Volumn 163, Issue 12, 2006, Pages 2080-2089

  Rosenheck, Robert A ^a   Leslie, Douglas L ^b   Sindelar, Jody ^b   Miller, Edward A ^b   Lin, Haiqun ^b   Stroup, T Scott ^b   McEvoy, Joseph ^b   Davis, Sonia M ^b   Keefe, Richard S E ^b   Swartz, Marvin ^b   Perkins, Diana O ^b   Hsiao, John K ^b   Lieberman, Jeffrey ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 33846276906     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2006.163.12.2080     Document Type: Article

References (33)

1. Duggan M: Do new prescription drugs pay for themselves? the case of second-generation antipsychotics. J Health Economics 2005; 24:1-31
2. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-564
3. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA: Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41:850-854
4. Reid WH, Mason M: Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. J Clin Psychiatry 1998; 59:189-194
5. Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G: Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomized clinical trial. Pharmacoeconomics 1999; 15:469-480
6. Essock SM, Frisman LK, Covell NH, Hargreaves W: Cost-effectiveness of clozapine compared with conventional antipsychotic medications for patients in state hospitals. Arch Gen Psychiatry 2000; 57:987-994
7. Rosenheck RA, Cramer J, Xu W, Thomas J, Henderson W, Frisman LK, Fye C, Charney D, for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia: A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337:809-815
8. Rosenheck RA, Perlick D, Bingham S, Liu-Mares, Collins J, Warren S, Leslie D, for the Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 2003; 290:2693-2702
9. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of effect on quality of life of second generation versus first generation antipsychotic drugs in schizophrenia - CUtLASS1. Arch Gen Psychiatry (in press)
10. Lieberman JA, Stroup S, McEvoy J, Swartz M, Rosenheck R, Perkins D, Keefe RSE, Davis S, Davis CE, Hsiao J, Severe J, Lebowitz B, for the CATIE Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. N Engl J Med 2005; 353:1209-1223
11. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I and II Disorders, version 2.0. New York, New York State Psychiatric Institute, Biometrics Research, 1995
12. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29:15-31
13. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost Effectiveness in Health and Medicine. New York, Oxford University Press, 1996
14. Drug Topics Red Book. Montvale, NJ, Medical Economics Company, 1999
15. Department of Health and Human Services, Office of Inspector General (2005): Medicaid Drug Price Comparisons: Average Manufacturer Price to Published Prices (http://oig.hhs.gov/oei/ reports/oei-03-05-00200.pdf, last viewed on November 23, 2005)
16. Rosenheck RA, Leslie DL, Sernyak ME: From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Medical Care 2001; 39:302-308
17. Thompson Medstat Group: Marketscan Communical Claims and Encounters Database. Ann Arbor, Mich, Thompson Medstat Group, 2002
18. Lenert L, Sturley AP, Rapaport MH, Chavez S, Mohr P, Rupnow M: Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative syndrome scale scores. Schizophr Res 2004; 71:155-165
19. Lenert L, Sturly AP, Rupnow M: Toward improved methods for measurement of utility: automated repair of errors in utility elicitations. Med Decis Mak 2003; 23:1-9
20. Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, Lehman AF, Lenert LA, Mahmoud R, Marder SR, Neumann PJ: The heterogeneity of schizophrenia in disease states. Schizophr Res 2004; 71:83-95
21. Kay SR, Fiszbein A, Opler L: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
22. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800-802
23. Tabachnick B, Fidell L: Using Multivariate Statistics (4th Edition) Boston, Allen and Bacon, 2000
24. Duan N: Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983; 78:605-610
25. Manning WG, Mullahy J: Estimating log models: to transform or not to transform? J Health Econ 2001; 20:461-494
26. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414-425
27. Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R: Nithsdale Schizophrenia Surveys 23: movement disorders. Br J Psychiatry 2002; 181:422-427
28. Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shubnan KI, Stukel T, Normand S-L, Rochon P: Antipsychotic medication and drug-induced movement disorder: a population-based cohort study in older adults. J Am Geriatr Soc 2005; 53:1374-1379
29. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, Normand S-L T, Mamdani M, Lee PE, Li P, Bronskill SE, Marras C, Gurwitz JH: Atypical antipsychotics and parkinsonism. Arch Intern Med 2005; 165:1882-1888
30. Woods S, Saksa JR, Walsh B, Sullivan MC, Morganstern H, Glazer W: Tardive Dyskinesia in a Community Mental Health Center: 2000-2005 (submitted)
31. Rosenheck RA: Efficacy vs. effectiveness of second generation antipsychotics: haloperidol without prophylactic anticholinergics as a comparitor. Psychiatr Serv 2005; 56:85-92
32. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589
33. Daniels N, Sabin J: Setting Limits Fairly: Can We Learn to Share Medical Resources? New York, Oxford, 2003